Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120843 | 0.86 | MCHR1 (0.39) | KDM4EALDH1A1POLBHPGDMAPT | |
| SCHEMBL2120299 | 0.85 | METTL3 (0.41) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL2121709 | 0.83 | KDM4E (0.45) | KDM4EALDH1A1TDP1HPGDHSD17B10 | |
| SCHEMBL2512855 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL2122874 | 0.80 | HCRTR1 (0.35) | ALDH1A1L3MBTL1HCRTR1HCRTR2PDE10A | |
| SCHEMBL2122900 | 0.79 | KDM4E (0.34) | KDM4EALDH1A1POLBL3MBTL1HPGD | |
| SCHEMBL311401 | 0.78 | PDE8B (0.32) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL2538401 | 0.77 | KDM4E (0.33) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL2533055 | 0.77 | KDM4E (0.35) | KDM4EALDH1A1HPGDHSD17B10HCRTR1 | |
| SCHEMBL2121865 | 0.75 | KDM4E (0.46) | KDM4EALDH1A1POLBHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, GPR119 | KDM4E 769/4885ALDH1A1 761/4885POLB 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.